IRS to Kickoff Audit Campaign Focused on Business Aircraft Users
What You Need to Know
Key takeaway #1
Individual and corporate taxpayers that improperly reported personal aircraft use as business use may face increased taxable income and penalties and/or denial of deductions.
Key takeaway #2
Corporate taxpayers that allocated the affiliated individual’s use of the corporate jet as business use may be denied deduction of such use.
Key takeaway #3
Taxpayers may wish to preemptively audit the prior deductions and, if the target of an IRS audit, seek advice from tax professionals with specific expertise in business aviation tax and IRS audits.
Client Alert | 1 min read | 02.29.24
Last week, the IRS announced plans to begin a campaign to audit personal use of business aircraft. The audits will focus on whether large corporations, partnerships and high-and ultra-high net worth aircraft owners have properly reported their business and personal aircraft usage for tax purposes, with a particular focus on ensuring that owners are only taking deductions to which they are entitled. Given the value of an aircraft, the amount of a deduction for aircraft related expenditures on a given taxpayer’s return can be in the tens of millions of dollars, and with more than 10,000 corporate jets operating in the U.S., IRS Commissioner Daniel Werfel recognized that much is at stake with this campaign. The audit campaign is expected to focus initially on multinational and domestic corporations and complex partnerships but is expected to expand from there.
Insights
Client Alert | 4 min read | 08.29.25
Gender-Affirming Care Targeted for Potential False Claims Act Enforcement
On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments.
Client Alert | 4 min read | 08.28.25
9th Circuit Marches Forward to the Future Finding Digital Assets Are Protected Under Trademark Law
Client Alert | 2 min read | 08.27.25
CPSC Maintains Momentum on eFiling Requirements for Consumer Products
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions